TrialLancet (London, England)2024

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Hans Gelderblom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.